Rydar Equities’s Novartis NVS Stock Holding History

Rydar Equities’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-2,630	Closed	-$318K	–	99
2025 Q2	$318K	Buy	+2,630	New	+$296K	0.25%	75

Other funds holding NVS

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Rydar Equities's NVS Position: Q3 2025 in Review

Rydar Equities sold out of Novartis (NVS) in Q3 2025, closing a stake of 2,630 shares — an estimated $318K sold.

Rydar Equities first reported a position in NVS in Q2 2025 and held it in 1 quarter. The position peaked at $318K in Q2 2025. 1,400 funds tracked by Wall St. Rank hold NVS as of Q3 2025.

Rydar Equities reported no remaining Novartis position as of Q3 2025 after selling out during the quarter.
Rydar Equities sold 2,630 Novartis shares in Q3 2025, an estimated $318K.
Rydar Equities first reported a position in Novartis in Q2 2025 and held it in 1 quarter.
Rydar Equities's Novartis position peaked at $318K in Q2 2025.
1,400 funds tracked by Wall St. Rank held Novartis as of Q3 2025.

Based on Rydar Equities's 13F filing for Q3 2025, filed 10 Oct 2025.